Venetoclax retreatment of patients with chronic lymphocytic leukemia after a previous venetoclax-based regimen.
Thompson MC, Harrup RA, Coombs CC, Roeker LE, Pu JJ, Choi MY, Barr PM, Allan JN, Šimkovič M, Leslie L, Rhodes J, Chong EA, Kamdar M, Skarbnik A, Lansigan F, McCall B, Saja K, Dyer MJS, Walter HS, Lefebure M, Thadani-Mulero M, Boyer M, Biondo J, Sail K, Manzoor BS, Furman R, Bantilan KS, Goy A, Feldman T, Labella D, Schuster SJ, Park J, Palomba L, Zelenetz A, Eyre TA, Kater AP, Seymour JF, Mato AR.
Thompson MC, et al. Among authors: mccall b.
Blood Adv. 2022 Aug 9;6(15):4553-4557. doi: 10.1182/bloodadvances.2022007812.
Blood Adv. 2022.
PMID: 35736670
Free PMC article.
No abstract available.